158 related articles for article (PubMed ID: 33833342)
1. Olig2 regulates p53-mediated apoptosis, migration and invasion of melanoma cells.
Lee JE; Ahn S; Jeong H; An S; Myung CH; Lee JA; Hong SC; Kim YJ; Kim JY; Ryu JH; Noh M; Nam KT; Hwang JS
Sci Rep; 2021 Apr; 11(1):7778. PubMed ID: 33833342
[TBL] [Abstract][Full Text] [Related]
2. Harnessing OLIG2 function in tumorigenicity and plasticity to target malignant gliomas.
Kosty J; Lu F; Kupp R; Mehta S; Lu QR
Cell Cycle; 2017 Sep; 16(18):1654-1660. PubMed ID: 28806136
[TBL] [Abstract][Full Text] [Related]
3. Post-translational Modifications of OLIG2 Regulate Glioma Invasion through the TGF-β Pathway.
Singh SK; Fiorelli R; Kupp R; Rajan S; Szeto E; Lo Cascio C; Maire CL; Sun Y; Alberta JA; Eschbacher JM; Ligon KL; Berens ME; Sanai N; Mehta S
Cell Rep; 2016 Jul; 16(4):950-966. PubMed ID: 27396340
[TBL] [Abstract][Full Text] [Related]
4. Olig2-Dependent Reciprocal Shift in PDGF and EGF Receptor Signaling Regulates Tumor Phenotype and Mitotic Growth in Malignant Glioma.
Lu F; Chen Y; Zhao C; Wang H; He D; Xu L; Wang J; He X; Deng Y; Lu EE; Liu X; Verma R; Bu H; Drissi R; Fouladi M; Stemmer-Rachamimov AO; Burns D; Xin M; Rubin JB; Bahassi EM; Canoll P; Holland EC; Lu QR
Cancer Cell; 2016 May; 29(5):669-683. PubMed ID: 27165742
[TBL] [Abstract][Full Text] [Related]
5. Oligodendrocyte lineage transcription factor 2 inhibits the motility of a human glial tumor cell line by activating RhoA.
Tabu K; Ohba Y; Suzuki T; Makino Y; Kimura T; Ohnishi A; Sakai M; Watanabe T; Tanaka S; Sawa H
Mol Cancer Res; 2007 Oct; 5(10):1099-109. PubMed ID: 17951409
[TBL] [Abstract][Full Text] [Related]
6. Novel HSP90 inhibitor NVP-HSP990 targets cell-cycle regulators to ablate Olig2-positive glioma tumor-initiating cells.
Fu J; Koul D; Yao J; Wang S; Yuan Y; Colman H; Sulman EP; Lang FF; Yung WK
Cancer Res; 2013 May; 73(10):3062-74. PubMed ID: 23492364
[TBL] [Abstract][Full Text] [Related]
7. RASSF8 regulates progression of cutaneous melanoma through nuclear factor-κb.
Wang J; Hua W; Huang SK; Fan K; Takeshima L; Mao Y; Hoon DS
Oncotarget; 2015 Oct; 6(30):30165-77. PubMed ID: 26334503
[TBL] [Abstract][Full Text] [Related]
8. FGFR3 promotes the growth and malignancy of melanoma by influencing EMT and the phosphorylation of ERK, AKT, and EGFR.
Li L; Zhang S; Li H; Chou H
BMC Cancer; 2019 Oct; 19(1):963. PubMed ID: 31619201
[TBL] [Abstract][Full Text] [Related]
9. A small-molecule antagonist of CXCR1 and CXCR2 inhibits cell proliferation, migration and invasion in melanoma via PI3K/AKT pathway.
Shang FM; Li J
Med Clin (Barc); 2019 Jun; 152(11):425-430. PubMed ID: 30340844
[TBL] [Abstract][Full Text] [Related]
10. The epithelial-mesenchymal transition (EMT) regulatory factor SLUG (SNAI2) is a downstream target of SPARC and AKT in promoting melanoma cell invasion.
Fenouille N; Tichet M; Dufies M; Pottier A; Mogha A; Soo JK; Rocchi S; Mallavialle A; Galibert MD; Khammari A; Lacour JP; Ballotti R; Deckert M; Tartare-Deckert S
PLoS One; 2012; 7(7):e40378. PubMed ID: 22911700
[TBL] [Abstract][Full Text] [Related]
11. Gambogic acid exhibits anti-metastatic activity on malignant melanoma mainly through inhibition of PI3K/Akt and ERK signaling pathways.
Li CY; Wang Q; Wang XM; Li GX; Shen S; Wei XL
Eur J Pharmacol; 2019 Dec; 864():172719. PubMed ID: 31586634
[TBL] [Abstract][Full Text] [Related]
12. The increased expression of Y box-binding protein 1 in melanoma stimulates proliferation and tumor invasion, antagonizes apoptosis and enhances chemoresistance.
Schittek B; Psenner K; Sauer B; Meier F; Iftner T; Garbe C
Int J Cancer; 2007 May; 120(10):2110-8. PubMed ID: 17266041
[TBL] [Abstract][Full Text] [Related]
13. Plumbagin suppresses the migration and invasion of glioma cells via downregulation of MMP-2/9 expression and inaction of PI3K/Akt signaling pathway in vitro.
Chen G; Yue Y; Qin J; Xiao X; Ren Q; Xiao B
J Pharmacol Sci; 2017 May; 134(1):59-67. PubMed ID: 28506595
[TBL] [Abstract][Full Text] [Related]
14. Twist induces epithelial-mesenchymal transition and cell motility in breast cancer via ITGB1-FAK/ILK signaling axis and its associated downstream network.
Yang J; Hou Y; Zhou M; Wen S; Zhou J; Xu L; Tang X; Du YE; Hu P; Liu M
Int J Biochem Cell Biol; 2016 Feb; 71():62-71. PubMed ID: 26693891
[TBL] [Abstract][Full Text] [Related]
15. Hydroxysafflor yellow A inhibited lipopolysaccharide-induced non-small cell lung cancer cell proliferation, migration, and invasion by suppressing the PI3K/AKT/mTOR and ERK/MAPK signaling pathways.
Jiang M; Zhou LY; Xu N; An Q
Thorac Cancer; 2019 Jun; 10(6):1319-1333. PubMed ID: 31055884
[TBL] [Abstract][Full Text] [Related]
16. Luteolin inhibits proliferation and induces apoptosis of human melanoma cells in vivo and in vitro by suppressing MMP-2 and MMP-9 through the PI3K/AKT pathway.
Yao X; Jiang W; Yu D; Yan Z
Food Funct; 2019 Feb; 10(2):703-712. PubMed ID: 30663726
[TBL] [Abstract][Full Text] [Related]
17. The oligodendrocyte lineage transcription factor 2 (OLIG2) is epigenetically regulated in acute myeloid leukemia.
Yalcin A; Kovarbasic M; Wehrle J; Claus R; Becker H; Abdelkarim M; Gaidzik VI; Schmidts A; Wäsch R; Pahl HL; Döhner K; Bullinger L; Duyster J; Lübbert M; Hackanson B
Exp Hematol; 2017 Nov; 55():76-85.e3. PubMed ID: 28760688
[TBL] [Abstract][Full Text] [Related]
18. The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells.
Niessner H; Beck D; Sinnberg T; Lasithiotakis K; Maczey E; Gogel J; Venturelli S; Berger A; Mauthe M; Toulany M; Flaherty K; Schaller M; Schadendorf D; Proikas-Cezanne T; Schittek B; Garbe C; Kulms D; Meier F
J Invest Dermatol; 2011 Feb; 131(2):468-79. PubMed ID: 20944654
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms of OLIG2 transcription factor in brain cancer.
Tsigelny IF; Kouznetsova VL; Lian N; Kesari S
Oncotarget; 2016 Aug; 7(33):53074-53101. PubMed ID: 27447975
[TBL] [Abstract][Full Text] [Related]
20. Effect of microRNA-135a on Cell Proliferation, Migration, Invasion, Apoptosis and Tumor Angiogenesis Through the IGF-1/PI3K/Akt Signaling Pathway in Non-Small Cell Lung Cancer.
Zhou Y; Li S; Li J; Wang D; Li Q
Cell Physiol Biochem; 2017; 42(4):1431-1446. PubMed ID: 28715819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
